Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies

Mantia-Smaldone, GM and Edwards, RP and Vlad, AM (2011) Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies. Cancer Management and Research, 3 (1). 25 - 38.

[img]
Preview
PDF
Available under License : See the attached license file.

Download (228kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. Prognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respond to available therapies. Emerging treatment strategies have subsequently focused on targets which are integral to tumor growth and metastasis. In this review, we will focus on those innovative agents currently under investigation in clinical trials. © 2011 Mantia-Smaldone et al, publisher and licensee Dove Medical Press Ltd.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Mantia-Smaldone, GM
Edwards, RPrpe1@pitt.eduRPE10000-0003-0370-1390
Vlad, AManvst12@pitt.eduANVST12
Date: 31 January 2011
Date Type: Publication
Journal or Publication Title: Cancer Management and Research
Volume: 3
Number: 1
Page Range: 25 - 38
Refereed: Yes
Article Type: Review
Date Deposited: 12 Dec 2012 20:49
Last Modified: 23 Jan 2019 05:55
URI: http://d-scholarship.pitt.edu/id/eprint/16858

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item